ARHP is supporting an important effort by the Planned Parenthood Federation of America (PPFA). Courtney Benedict, MSN, CNM, FNP of PPFA is conducting a survey of advanced practice clinicians (APCs), including nurse practitioners, nurse-midwives, licensed midwives and physician assistants, to assess their interest and engagement in working in the delivery of sexual and reproductive health (SRH) care. Specifically, this survey will:

• Ask about your interest in and motivations for working in SRH
• Identify needs of APCs interested in SRH work and
• Identify needs of APCs already engaged in SRH

This survey is part of a larger organizational project seeking to define motivators and barriers to APC’s participation in the SRH workforce. The findings from this study will be analyzed and published as potential strategies for the recruitment and retention of APCs in the SRH workforce.

Your participation in this survey is voluntary and you can stop participation at any time. Your answers are anonymous and the data will be kept confidential and only shared publicly in aggregated forms which would prevent identification of individual responses.

This survey should take approximately 15-20 minutes to complete and for your participation, you will have the option to be entered into a raffle to win one of several $250 gift cards. Your valuable time and insight is appreciated.

If you have any questions, please contact Courtney Benedict at Courtney.benedict@ppfa.org or at 415-828-1487.

Click Here to Take the Survey

December 11, 2018, MedPage Today  

Results of the 30-year prospective University of Kentucky Ovarian Cancer Screening Trial are adding to a body of evidence suggesting that an annual transvaginal ultrasound can detect early-stage ovarian cancer and improve survival rates for this patient population.

Read more.

December 11, 2018, MedPage Today  

Women's risk of breast cancer was highest about 5 years after childbirth, and lasted more than 20 years, compared with women who have never given birth, and breastfeeding did not appear to attenuate the risk, a large pooled analysis found. 

Read more.

December 7, 2018, MedPage Today  

Obesity may diminish survival in women with CLL who undergo chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR), a study from Germany found. 

Read more.

December 6, 2018, Monthly Prescribing Reference b 

Menopausal hormone therapy appears to reduce the risk of carpal tunnel syndrome in postmenopausal women, according to a study published in Plos One. To investigate the association between hormone therapy and carpal tunnel syndrome risk, researchers conducted a secondary analysis of the Women's Health Initiative (WHI) hormone therapy trials.  

Read more.

December 6, 2018, HemOnc Today 

Adjuvant ado-trastuzumab emtansine reduced risk for invasive recurrence by 50 percent compared with trastuzumab among patients with HER2-positive early breast cancer who still had residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy, according to results of the KATHERINE trial presented at San Antonio Breast Cancer Symposium. 

Read more.

APAOG Annual Meeting Sponsorship Opportunities

Consider sponsoring the APAOG Reception at the 2019 AAPA Annual Conference in Denver, CO!

Event Details:

Sunday, May 19th
Time : TBD (evening) 
Location: TBD 
Denver, CO

Sponsorship Details:

• $5,000 Exclusive Sponsor 
  
• $2,500 Partner Sponsor
  
• $1,000 Affiliate Sponsor

Exclusive Sponsor - 1 at $5,000 

Includes Partner and Affiliate benefits listed below, as well as dedicated time to present at the event.

Partner Sponsor - 1 at  $2,500

Includes all Affiliate benefits below and:

• Recognition on the website and all event promotion

• Opportunity to place materials at APAOG Exhibit Booth at AAPA.

• One quarter of advertising on APAOG website

Affiliate Sponsor - 1 at $1,000

Affiliate Sponsor Package Includes:

• 2019 Affiliate APAOG Membership

• Recognition on Welcome Signs at Event

• Logo included on Email invitation to attendees. 

Learn more here.

November 30, 2018, National Institutes of Health via Medical Xpress  

NIBIB-funded researchers recently validated a rapid STD test that delivered accurate results in about 30 minutes for chlamydia, allowing patients to receive treatment immediately, thereby stemming the further spread of disease. Other analyses showed most women preferred the easy self-collection method the test offers.

Read more. 

November 29, 2018, MedPage Today   

While prenatal ultrasound imaging detected fetal abnormalities among most infants with intrauterine exposure to Zika virus, a few had abnormalities that were only seen during postnatal imaging, researchers found. 

Read more.

November 29, 2018, Medscape  

A novel test engineered from a bacterial toxin has been shown to detect significant levels of a specific biomarker released into the blood by ovarian cancer cells at all stages of the disease, including the early stages, distinguishing patients with ovarian cancer from healthy unaffected controls, research indicates. 

Read more.